A study on the effect of diabetes drugs (SGLT2 inhibitor and DPP4 inhibitor) for nonalcoholic fatty liver disease

A study on the effect of diabetes drugs (SGLT2 inhibitor and DPP4 inhibitor) for nonalcoholic fatty liver disease - A study on the effect of diabetes drugs (SGLT2 inhibitor and DPP4 inhibitor) for nonalcoholic fatty liver disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027304

Enrollment

Registered

2017-05-15

Start date

2017-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonalcoholic fatty liver disease

Interventions

For 12 weeks, dapagliflozin 5 mg is administered daily. For 12 weeks, tengliptin 5 mg is administered daily.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Nonalcoholic fatty liver disease case without diabetes mellitus

Exclusion criteria

Exclusion criteria: Cases with severe heart, liver and kidney disease

Design outcomes

Primary

Measure	Time frame
The rate of change of ALT value after 12 weeks from the start of administration	—

Countries

Japan

Contacts

Public ContactTobita Hiroshi

Shimane University Hospital Department of Hepatology

ht1020@med.shimane-u.ac.jp0853-20-2190

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026